Svennerholm L, Vanier M T, Häkansson G, Mänsson J E
Clin Chim Acta. 1981 May;112(3):333-42. doi: 10.1016/0009-8981(81)90456-3.
The optimal conditions for the assay of the cerebroside-beta-galactosidase deficiency in Krabbe disease were studied. Labelled galactosylceramides and lactosylceramides isolated from natural sources were both suitable substrates provided that the lipophilic moieties were identical in labelled and unlabelled portions. Galactosylceramides and lactosylceramides with uniform fatty acid compositions were also tested. The highest specific cerebroside-beta-galactosidase activities were obtained with N-palmitoyl galactosyl- and lactosylceramides. The chromogenic substrate 2-hexadecanoyl-amino-4-nitrophenyl-beta-D-galactopyranoside (HNGal) was shown to be an unreliable substrate requiring large amounts of enzyme protein and giving false normal results. Krabbe disease was diagnosed in 45 patients. With galactosylceramides as substrates the residual cerebroside-beta-galactosidase activity was 7%, with lactosylceramides 8%, and there was no overlap in enzyme activity between the 45 patients and 42 parents. Approximately 50% of the obligate carriers had values within the range for the normal controls, independently of which substrate was used.
研究了测定克拉伯病中脑苷脂β - 半乳糖苷酶缺乏症的最佳条件。从天然来源分离的标记半乳糖神经酰胺和乳糖神经酰胺都是合适的底物,前提是标记部分和亲脂部分的亲脂基团相同。还测试了具有均匀脂肪酸组成的半乳糖神经酰胺和乳糖神经酰胺。使用N - 棕榈酰半乳糖神经酰胺和乳糖神经酰胺时,脑苷脂β - 半乳糖苷酶的比活性最高。显色底物2 - 十六烷酰氨基 - 4 - 硝基苯基 - β - D - 吡喃半乳糖苷(HNGal)被证明是一种不可靠的底物,需要大量的酶蛋白,并且会给出假正常结果。45名患者被诊断为克拉伯病。以半乳糖神经酰胺为底物时,脑苷脂β - 半乳糖苷酶的残余活性为7%,以乳糖神经酰胺为底物时为8%,45名患者和42名父母之间的酶活性没有重叠。大约50%的 obligate 携带者的值在正常对照范围内,与使用哪种底物无关。